IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4684
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$53M
Simon Allen
Anebulo Pharmaceuticals, Inc. engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. The company was incorporated in 2020 and is based in Lakeway, Texas.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ANEB Anebulo Pharmaceuticals, Inc. | 27 | 19 | 19 | 11 | - | - | -104.5% | -88.1% | - | - | - | - | 0.0% | 19.0x | $53M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Anebulo Pharmaceuticals, Inc. (ANEB) receives a "Avoid" rating with a composite score of 27.1/100. It ranks #4684 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ANEB.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 19 | 3 | +16ALPHA |
| MOMENTUM | 11 | 3 | +8ALPHA |
| VALUATION | 19 | 9 | +10ALPHA |
| INVESTMENT | 29 | 33 | -4NEUTRAL |
| STABILITY | 34 | 21 | +13ALPHA |
| SHORT INT | 83 | 92 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -104.5% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 5yr history
Interest coverage -154.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Anebulo Pharmaceuticals, Inc. (ANEB) as Avoid with a composite score of 27.1/100 at a current price of $0.44. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Anebulo Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 27.1/100 places it at rank #4684 in our full universe.
No Moat
Medium
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Anebulo Pharmaceuticals, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Anebulo Pharmaceuticals, Inc. with an Avoid rating, assigning a composite score of 27.1/100 and 1 out of 5 stars. Ranked #4684 of 7,333 stocks, ANEB falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Anebulo Pharmaceuticals, Inc. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of -104.5% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
ANEB registers a value score of just 19/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 2.42x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Anebulo Pharmaceuticals, Inc.'s investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -88.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Anebulo Pharmaceuticals, Inc. is experiencing notably weak momentum with a score of just 11/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.01 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
ANEB's stability score of 34/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.01 and a debt-to-equity ratio of 19.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
ANEB's short interest factor score of 83/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 19.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $53M, Anebulo Pharmaceuticals, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Anebulo Pharmaceuticals, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4684 of 7,333 overall (36th percentile). Key comparisons include ROE of -104.5% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ANEB currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (11) would have the largest impact on the composite score.
ROE 5402% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 8948% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
AUSTIN, Texas, February 12, 2026--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2025, and recent updates.
AUSTIN, Texas, February 06, 2026--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Company’s board of directors (the "Board") has approved the voluntary delisting of the Company’s common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Secur
AUSTIN, Texas, January 29, 2026--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026.
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Assembly Biosciences, Inc. (NASDAQ: ASMB) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies. Olink Holding AB (NASDAQ: OLK) shares climbed 65.8% to $24.84 after Thermo Fisher Scientific announced it will acquire the company. MoneyHero Limited (NASDAQ: MNY) surged 33.7% to $3.40. OpGen, Inc. (NASDAQ: OPGN) gained 32.7% to $1.20. FLJ Group Limited (NASDAQ: FLJ) jumped 29.3% to $0.2689. Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) gained 22.5% to $2.0950. Ramaco Resources, Inc. (NASDAQ: METC) rose 20.2% to $11.73. Aurora Mobile Limited (NASDAQ: JG) shares climbed 19.8% to $0.1593 after gaining 8% on Monday. Nkarta, Inc. (NASDAQ: NKTX) rose 18.5% to $1.75 as the company received FDA clearance of IND application for NKX019 in lupus nephritis. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) gained 18% to $3.0905. Gamer Pakistan Inc. (NASDAQ: GPAK) gained 16.8% to $1.46. Summit Therapeutics Inc. (NASDAQ: SMMT) rose 16% to $2.03. Meiwu Technology Company Limited (NASDAQ: WNW) shares rose 15.4% to $0.1062 after falling 4% on Monday. WiSA Technologies, Inc. (NASDAQ: WISA) shares gained 12.8% to $0.28 after falling 40% on Monday. WiSA Technologies announced pricing of ...
H.C. Wainwright has initiated coverage on Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) with a Buy rating and a price target of $6. Anebulo Pharmaceuticals is an emerging specialty biopharmaceutical company with a primary focus on developing therapy for acute cannabinoid intoxication (ACI), presenting a unique opportunity as approximately 2.1 million ACI cases are reported in U.S. emergency departments annually. The company has produced compelling clinical proof-of-concept data, employing a visual analog scale (VAS) methodology to measure the substantial reduction in ACI symptoms, particularly the alteration in the sensation ...Full story available on Benzinga.com